{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:37:52Z","timestamp":1791027472851,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ymgme.2011.02.006","type":"journal-article","created":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T15:31:26Z","timestamp":1297783886000},"page":"107-112","source":"Crossref","is-referenced-by-count":68,"title":["Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle"],"prefix":"10.1016","volume":"103","author":[{"given":"Dwight D.","family":"Koeberl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McVie-Wylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhrad G.","family":"Banugaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha S.","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2011.02.006_bb0005","series-title":"The Metabolic and Molecular Basis for Inherited Disease McGraw-Hill, New York","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid {alpha}-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0020","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0002-9440(10)65361-8","article-title":"Murine acid \u03b1-glucosidase: cell-specific mRNA differential expression during development and maturation","volume":"154","author":"Ponce","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0030","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study","volume":"20","author":"Van Capelle","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1468-1331.2010.02959.x","article-title":"Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis","volume":"17","author":"Ravaglia","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0040","first-page":"132","article-title":"Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"Desnick","year":"2004","journal-title":"J Inher Metab Dis"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Molecr Genet Metab"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0060","first-page":"712","article-title":"Carbohydrate-remodeled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"15","author":"Zhu","year":"2005","journal-title":"Neuromuscr Dis"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0065","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"Mcvie-Wylie","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"Pathogenetics"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.archoralbio.2006.01.003","article-title":"The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat","volume":"51","author":"Matsumoto","year":"2006","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0085","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid \u03b1-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1097-2765(00)80155-0","article-title":"A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance","volume":"2","author":"Bruning","year":"1998","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1152\/physrev.00028.2007","article-title":"Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease","volume":"88","author":"Lynch","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1152\/physiol.00041.2007","article-title":"Signaling in muscle atrophy and hypertrophy","volume":"23","author":"Sandri","year":"2008","journal-title":"Physiol. Bethesda"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00424-006-0122-1","article-title":"Molecular impact of clenbuterol and isometric strength training on rat EDL muscles","volume":"453","author":"Mounier","year":"2007","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1042\/bj2640573","article-title":"Effects of clenbuterol and propranolol on muscle mass, evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy","volume":"264","author":"Maclennan","year":"1989","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0115","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1152\/ajpendo.2002.282.1.E31","article-title":"Role of IGF-1 and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol","volume":"282","author":"Awede","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0120","doi-asserted-by":"crossref","first-page":"C1681","DOI":"10.1152\/ajpcell.00466.2006","article-title":"Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles","volume":"292","author":"Shi","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/mus.20684","article-title":"Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle","volume":"35","author":"Burniston","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1027377731137","article-title":"Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses","volume":"24","author":"Plant","year":"2003","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0135","first-page":"390","article-title":"Adult form of acid maltase deficiency presenting with pattern of muscle weakness resembling facioscapulohumeral dystrophy","volume":"41","author":"Oya","year":"2001","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjp.0706669","article-title":"Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses","volume":"147","author":"Ryall","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1113\/jphysiol.2003.056770","article-title":"Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats","volume":"555","author":"Ryall","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0150","first-page":"A369","article-title":"An open trial of albuterol and branched chain aminoacids in adult acid maltase deficiency","volume":"50","author":"Angelini","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.006_bb0155","first-page":"71\/78","article-title":"Adult acid maltase deficiency: an open trial with albuterol and branched-chain aminoacids","volume":"14","author":"[31]","year":"2004","journal-title":"Basic Appl. Myol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0002-9440(10)63823-0","article-title":"Tissue-specific inactivation of murine M6P\/IGF2R","volume":"162","author":"Wylie","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2011.02.006_bb0170","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Nat. Acad. Sci. U.S.A."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T15:06:43Z","timestamp":1560006403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719211000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1096719211000497"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2011.02.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}